头颈部原发鼻窦与皮肤肿瘤的海马保护放疗
本研究回顾性选取30例在学术医疗中心接受根治性治疗的鼻窦或皮肤头颈部原发恶性肿瘤患者,基于原靶区和危及器官体积重新制定海马保护调强放疗计划。海马保护计划使同侧海马Dmax中位数从3586 cGy降至2009 cGy(相对降低44%),D100%从1257 cGy降至434 cGy(相对降低65%),而PTV覆盖和其他危及器官剂量无统计学显著或临床意义差异。作者建议在可行时采用海马Dmax<1600 cGy、D100%<500 cGy的目标约束,并认为其临床意义应在前瞻性研究中探讨。
要点
- 30例鼻窦或皮肤头颈部原发肿瘤患者重新制定海马保护调强放疗计划。
- 同侧海马Dmax中位数从3586 cGy降至2009 cGy,相对降低44%。
- 同侧海马D100%中位数从1257 cGy降至434 cGy,相对降低65%。
核心结论
- 海马保护放疗可行,可显著降低海马剂量而不降低PTV覆盖或增加其他危及器官剂量。
- 作者建议在可行时(不损害PTV覆盖或不影响其他关键危及器官)采用海马Dmax<1600 cGy和D100%<500 cGy的目标约束。
- 海马保护放疗在头颈部原发肿瘤患者中的临床意义应在前瞻性研究中探讨。
研究设计与样本
- 回顾性选取在学术医疗中心接受根治性治疗的鼻窦或皮肤头颈部原发恶性肿瘤患者。
- 所有患者接受单纯(放化疗)或辅助(放化疗),且单侧或双侧海马接受显著辐射剂量。
- 使用原始靶区和危及器官体积为每例患者制定新的海马保护调强放疗计划。
- 海马基于放射治疗肿瘤学组指南勾画,并由神经放射学家审核。
- 记录并比较海马、计划靶体积和危及器官的辐射剂量绝对与相对差异。
主要发现
- 共纳入30例患者,其中鼻窦原发肿瘤18例、皮肤头颈部原发肿瘤12例。
- 中位处方剂量为6600 cGy(范围5000-7440 cGy)。
- 30例患者中14例接受120 cGy/次、每日两次放疗,13例接受200 cGy/次、每日一次放疗,其余接受180-275 cGy/次、每日一次放疗。
- 海马保护放疗使同侧海马Dmax中位数从3586 cGy降至2009 cGy,相对降低44%。
- 海马保护放疗使同侧海马D100%中位数从1257 cGy降至434 cGy,相对降低65%。
关键数值与推荐
- 作者建议在可行时(不损害PTV覆盖或不影响其他关键危及器官)采用海马Dmax<1600 cGy的目标约束。
- 作者建议在可行时(不损害PTV覆盖或不影响其他关键危及器官)采用海马D100%<500 cGy的目标约束。
临床怎么用
- 对于鼻窦或皮肤头颈部原发恶性肿瘤患者,海马保护放疗可行,可在不降低PTV覆盖或不增加其他危及器官剂量下降低海马剂量。
- 作者建议在可行时(不损害PTV覆盖或不影响其他关键危及器官)采用海马Dmax<1600 cGy和D100%<500 cGy的目标约束。
- 海马保护放疗在该人群中的临床意义应在前瞻性研究中探讨。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with primary sinonasal and cutaneous head and neck (H&N) malignancies often receive meaningful radiation dose to their hippocampi, but this not a classic avoidance structure in radiation planning. We aimed to characterize the feasibility and tradeoffs of hippocampal-sparing radiation therapy (HSRT) for patients with primary sinonasal and cutaneous H&N malignancies. METHODS AND MATERIALS: We retrospectively selected patients who were treated definitively for primary sinonasal or cutaneous malignancies of the H&N at an academic medical center. All received (chemo)radiation alone or adjuvantly and substantial radiation dose to 1 or both hippocampi. We created new HSRT plans for each patient with intensity modulated radiation therapy using the original target and organ-at-risk (OAR) volumes. Hippocampi were contoured based on Radiation Therapy Oncology Group guidelines and reviewed by a neuroradiologist. Absolute and relative differences in radiation dose to the hippocampi, planning target volumes (PTVs), and OARs were recorded and compared. RESULTS: There were 18 sinonasal and 12 cutaneous H&N primary tumors (30 patients in total). Median prescription dose was 6600 cGy (range, 5000-7440 cGy), and 14 of the 30 patients received 120 cGy/fraction twice daily, 13 of the 30 patients received 200 cGy/fraction once daily, whereas others received 180-275 cGy/fraction once daily. The relative decrease in ipsilateral hippocampal Dmax and D100% using HSRT was 44% (median, 2009 cGy from 3586 cGy) and 65% (median 434 cGy from 1257 cGy), respectively. There were no statistically significant or clinically meaningful differences in PTV V100%, PTV D1%, or radiation dose to other OARs between HSRT and non-HSRT plans. CONCLUSIONS: HSRT is feasible and results in meaningful dose reduction to the hippocampi without reducing PTV coverage or increasing dose to other OARs. We suggest target hippocampal constraints of Dmax < 1600 cGy and D100% < 500 cGy when feasible (without compromising PTV coverage or impacting other critical OARs). The clinical significance of HSRT in patients with primary H&N tumors should be investigated prospectively.
引用
- Hall J, Dance M, Huang B, et al. Hippocampal-Sparing Radiation Therapy in Primary Sinonasal and Cutaneous Tumors of the Head and Neck. Adv Radiat Oncol. 2024. PMID: 39263446. doi:10.1016/j.adro.2024.101588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。